CN103893240A - Composition for preventing and/or treating respiratory system diseases caused by hazes - Google Patents
Composition for preventing and/or treating respiratory system diseases caused by hazes Download PDFInfo
- Publication number
- CN103893240A CN103893240A CN201410166161.8A CN201410166161A CN103893240A CN 103893240 A CN103893240 A CN 103893240A CN 201410166161 A CN201410166161 A CN 201410166161A CN 103893240 A CN103893240 A CN 103893240A
- Authority
- CN
- China
- Prior art keywords
- xylitol
- compositions
- respiratory system
- composition
- fructus momordicae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a xylitol-containing composition for preventing and/or treating respiratory system diseases caused by hazes. The composition is mainly prepared from xylitol and an fructus momordicae extract and can be prepared into an acceptable preparation, wherein the weight percent of the xylitol and the fructus momordicae extract in the composition accounts for 0.1% to 99.9%. The antibacterial ability of the composition is enhanced under the synergistic effect of the xylitol and the fructus momordicae extract. Not only the composition has obvious effects for preventing and treating the respiratory system diseases caused by the hazes and is convenient to take, but also the composition is a sugar alcohol without harm to human bodies and is sweet in taste, so that the respiratory system diseases caused by the hazes are prevented and treated while people are in enjoyment at the same time. The composition cannot perform any adverse effects on the taste of patients when being used for preventing and treating the respiratory system diseases caused by the hazes, thereby being easily accepted by multiple patients.
Description
Technical field
The invention belongs to field of health care products, especially relate to a kind of compositions that contains having of xylitol and prevent and/or treat haze respiratory system disease.
Background technology
Xylitol products is mainly take the agricultural wastes such as corn cob, bagasse as raw material, the white crystals body of preparing through processing steps such as hydrolysis, purification, hydrogenation, crystallization, centrifugal, oven dry, its odorless, taste are cool, sugariness is equivalent to sucrose, heat is equivalent to glucose, is a kind of very sweeting agent of high nutritive value that has.Because its metabolism does not need insulin, therefore can be used as diabetes patient's sugar succedaneum; Because it can not utilized by the streptococcus mutans fermentation in oral cavity, generation that therefore can caries prevention.
In recent years, along with the raising of people's living standard, the enhancing of health care consciousness, as the xylitol products with unique Physiological Properties, be no matter as medical product for clinical, or as food additive for remedy diet, be all more and more subject to consumers in general's favor, every year, with approximately 20% speed sustainable growth, market prospect is wide.State food Drug Administration management boards in 2002 are approved as xylitol diabetes patient's sugar substitute, and Ministry of Public Health in 2005 approval xylitol is applicable to various food, and meanwhile, xylitol also the aspect such as prepares at oil casting, war products to be had compared with multipurpose.
In recent years, scientist and Medical Technologist find by a large amount of experimental studies: xylitol is that many pathogenic bacterium are as the natural enemy of streptococcus, aerogenesis streptococcus, false silk streptococcus etc., it has good effect to preventing and treating mainly the upper respiratory tract infection causing because of streptococcus and viral infection, is the health care bodyguard of mankind's upper respiratory tract.But up to the present yet there are no any correlational study and report and the related application aspect the respiratory system disease that xylitol causes at the haze weather causing due to pollutant such as industrial waste gas, vehicle exhaust, building building cement dirt, coal smoke dirt, waste incineration, airborne dust, airborne antibacterial and viruses.
Along with the acceleration of Development of Urbanization and process of industrialization, industrial waste gas, vehicle exhaust, building building cement dirt, coal smoke dirt, the unordered discharge of the pollutant such as waste incineration, causes airborne dust, antibacterial, the pollutant severe overweights such as virus and pellet, they and fog combine, allow sky moment become gloomily gloomy, form haze weather, particularly in recent years, along with air quality runs down, the frequency that haze weather phenomenon occurs is more and more higher, under this weather, in the time of people's trip or routine work life, airborne molecule (mainly refers to that diameter is less than or equal to the particulate matter of 2.5 microns, be PM2.5, also referred to as entering lung particulate matter) will when having no to take precautions against, people invade in human respiratory tract and the lobe of the lung, cause haze respiratory system disease, as pharyngolaryngitis, irritated, asthma, rhinitis, sinusitis, emphysema etc., show as cough, expectoration, rhinorrhea, nasal obstruction, sneeze, the symptoms such as dry pharynx, for a long time in this environment, also can bring out pulmonary carcinoma, myocardial ischemia and damage, cause very large harm to human body.
The main cause that causes haze respiratory system disease is: after airborne molecule is sucked by human body, can stimulate and destroy respiratory system mucosa, the defence capability of respiratory system mucosa is reduced, cause the airborne streptococcus of haze, aerogenesis streptococcus, false silk streptococcus, virus etc. to enter respiratory system, make respiratory system infection, and then cause various haze respiratory system diseases.Prevention and the most direct method for the treatment of haze respiratory system disease are to reduce and go out and wear masks as far as possible, can only prevent that some dusts from entering nasal cavity but wear masks, play certain protective action, limited for PM2.5 and following its defensive ability/resistance ability of finely ground particles, do not reach the requirement of control, meanwhile, put on mask and manufactured artificially on the contrary respiratory disorder, causing patient respiratory difficulty, is not very applicable.Therefore, prevent and treat the respiratory system disease causing because of haze weather for preventing that it from further worsening and causing that the even more serious anxious critical illness of other system is significant.At present, general treatment is all to adopt antibiotic or use antihistaminic and other antiallergic agent, although but temporarily kill pathogens of a large amount of antibiotic, but also cultivate drug-fast superbacteria simultaneously, and frequency of utilization is higher, scope is wider, the time is longer, the drug resistance producing is stronger, causes curative effect to reduce.And antihistaminic and other antiallergic agent are anesthetics mostly, after use, can produce a lot of untoward reaction.
And report more mainly containing for the medicine, the health product research that prevent and treat the respiratory system disease causing because of haze weather: a kind of Chinese medicine composition for the treatment of the infringement of respiratory tract haze and preparation method thereof is disclosed in the Chinese patent literature of publication number CN103127369A, this Chinese medicine composition is made up of Radix Platycodonis, Bulbus Fritillariae Thunbergii, Fructus Momordicae, Radix Glycyrrhizae, there is dispersing and elevation lung qi, lung moistening is eliminated the phlegm, promote air flue self-cleaning ability, get rid of effect of the granule harmful substances such as haze, and have no side effect, in the Chinese patent literature of publication number CN103181565A, disclose a kind of anti-PM2.5 lung heat clearing and protected lung capsule, it is by Semen Ginkgo extrac, Semen Armeniacae Amarum extract, Bulbus Lilii extract, Radix Ophiopogonis extract, Agaricus campestris extract, Radix et Caulis Opuntiae Dillenii extract, Echinacea extract, Fructus Hippophae extract, sulforaphen, metallothionein, chlorophyll, the health food that sodium alginate etc. are made for raw material, there is lung heat clearing poison, lung moistening, foster lung protects lung, relieving cough and resolving phlegm, be used for removing rubbish in body, PM2.5 haze, organic compound, toxin expelling, antiviral, anti-inflammation, enhancing immunity, prevent and treat asthma, upper respiratory tract infection, emphysema, the effects such as bronchitis, the Chinese patent literature of publication number CN103405699A discloses a kind of beverage of preventing and treating the respiratory passage diseases that haze causes and preparation method thereof, this beverage is made up of Folium Mori, fresh Rhizoma Phragmitis, Semen pruni armeniacae, Bulbus Lilii, Radix Glehniae, the Radix Astragali, Radix Platycodonis, Radix Ophiopogonis, Pericarpium Citri Reticulatae, Rhizoma Alpiniae Officinarum, Bulbus Fritillariae Thunbergii, Flos Lonicerae, Semen Armeniacae Amarum, Mentholum, preparation is simple, and the symptom such as cough, abundant expectoration that haze is caused has good effect, the Chinese patent literature of publication number CN103583754A discloses a kind of moistening and cleaning throat except haze health-care tea beverage, this health-care tea beverage is by green tea, Rhizoma Dioscoreae, Semen sojae atricolor, Caulis et Folium Brassicae capitatae, Radix Dauci Sativae, teosinte, Nigella damascena L., Semen Ginkgo, Pleurotus ostreatus, Flos Lonicerae, Flos Chrysanthemi, Radix Isatidis, Rhizoma Zingiberis, Fructus Citri Sarcodactylis, Semen Sterculiae Lychnophorae, Folium Perillae, Radix Platycodonis, Fructus Gardeniae, Radix Glycyrrhizae, Fructus Phyllanthi, Bulbus Fritillariae Cirrhosae, Cortex Moutan, Mel, water is prepared from, adopt dual cavity packing material, can install tasty and refreshing feed liquid additional, have and remove the harmful substance of being brought into by haze micronic dust in body, reduce the effect of the harm of haze to human body.More than prevent and treat in the medicine of the respiratory system disease causing because of haze weather or the raw material of health product and all contain Chinese medicine ingredients, mouthfeel is bad, and preparation technology is numerous and diverse, and cost is higher.
Summary of the invention
For solving the problems of the technologies described above, the invention provides a kind of compositions that contains having of xylitol and prevent and/or treat haze respiratory system disease.
Compositions of the present invention, contains xylitol.
Compositions of the present invention, is mainly made up of xylitol and Fructus Momordicae extract.
Compositions of the present invention, can make acceptable preparation, and wherein xylitol and Fructus Momordicae extract shared percentage by weight in preparation is 0.1-99.9%.
Compositions of the present invention, contains xylitol and Fructus Momordicae extract, and xylitol and Fructus Momordicae extract produce synergism, can more effective bacteria growing inhibiting, play better effect.
The dosage form of compositions of the present invention is selected from: tablet, sugar coated tablet, film coated tablet, enteric coated tablet, capsule, hard capsule, soft capsule, oral liquid, suck agent, granule, electuary, pill, powder, unguentum, sublimed preparation, suspensoid, powder, solution, injection, suppository, ointment, plaster, cream, spray, drop or patch.
Compositions of the present invention, during for prevention and health-care effect, can select oral, respiratory system administering mode, and oral formulations can be liquid or solid form, such as making oral liquid, buccal tablet, capsule etc.; Do the used time when being used for the treatment of, preferably respiratory system administering mode, as made spray, drop, through focus, better effects if.
According to one of embodiment of the present invention, the xylitol that described tablet is 90-95% by quality percentage composition, the Fructus Momordicae extract of 0.2-5% form, and other surpluses are excipient.
Tablet of the present invention can contain conventional excipient, such as binding agent, filler, diluent, tablet agent, lubricant, disintegrating agent, coloring agent, flavoring agent and wetting agent, can carry out coating to tablet if desired.
Applicable filler comprises cellulose, mannitol, lactose and other similar filler.Suitable disintegrating agent comprises starch, polyvinylpyrrolidone and starch derivatives, for example sodium starch glycollate.Suitable lubricant comprises, for example magnesium stearate.The acceptable wetting agent of suitable medicine comprises sodium lauryl sulphate.Can, by mixing, fill, the method that tabletting etc. are conventional is prepared solid oral composition.Repeatedly mix and can make active substance be distributed in those compositionss of a large amount of filleies of whole use.
Compositions of the present invention, during for prevention and treatment haze respiratory system disease, the compositions that take in every day is counted 5-80g by xylitol quality, can reach the effect of prevention and treatment.
Preferably, the compositions of taking in every day is counted 5-15g by xylitol quality.
Preferred, the compositions that take in every day is counted 6-10g by xylitol quality.
According to one of embodiment of the present invention, in described oral liquid, the mass concentration of xylitol is 5-30%, and the mass concentration of Fructus Momordicae extract is 0.1-2%.
In described oral liquid, can conventionally select to add antiseptic as potassium sorbate, sodium benzoate etc.; essence and flavoring agent is as Fructus Citri Limoniae essence, apple essence, orange flavor etc.; nutrient substance is as taurine, vitamin, lecithin etc., for preventing corruption, adjust taste, strengthening nutrition.
Compositions of the present invention, have the following advantages: (1) is through research, applicant finds, xylitol, by the growth of the harmful bacterias such as the streptococcus in inhibition haze weather, aerogenesis streptococcus, false silk streptococcus, reaches the effect that prevents and/or treats haze respiratory system disease, can reduce people to antibiotic dependence, and can not produce drug resistance, and can adhere to for a long time eating, there is no toxic and side effects, play the effect of prevention and health care; Xylitol and Fructus Momordicae extract produce synergism simultaneously, have strengthened antibacterial ability; (2) product provided by the invention not only has significant prevention and therapeutic effect to haze respiratory system disease, taking convenience, and also xylitol products is a kind of health not to be had to prejudicial sugar alcohol, taste sweetness, can make people prevent and treat in enjoyment; (3) present composition, when haze respiratory system disease patient is played to preventive and therapeutic action, can not produce any harmful effect to patient's the sense of taste, is easy to be accepted by extensive patients.
The specific embodiment
Below in conjunction with specific embodiment, the invention will be further described.
Xylitol health product of the present invention are for preventing and to treat the principle of haze respiratory system disease as follows: the generation of general haze respiratory system disease is all to be caused by the streptococcus of haze weather, aerogenesis streptococcus, false silk streptococcus and viral infection, when antibacterial, virus enter after human body by nasal cavity, throat, can attack the mucosa of nose, larynx, even make a forcible entry into the respiratory apparatus such as ear, lung, cause respiratory system infection, cause respiratory system disease.In addition, the lung mucosa of Healthy People and respiratory tract surface are all covered with very thin one deck mucus, contain " endogenous antibiotic substance ", they are that human body is resisted in haze air harmful microorganism (as streptococcus, aerogenesis streptococcus, false silk streptococcus, virus etc.) and the interior safe natural cover for defense together of finely ground particles infringement body, if the salinity of this layer of mucus on respiratory tract and lung mucosa increases, will amount reproduction and accumulation on the surface of respiratory tract and lung mucosa from the airborne harmful microorganism of haze and finely ground particles, finally cause the respiratory system diseases such as pulmonary infection.Applicant finds that in clinical research process xylitol can suppress streptococcus, aerogenesis streptococcus, the streptococcic growth of false silk, and these several bacterium are the Etiologicals that cause haze respiratory system disease, when taking after xylitol, the harmful bacterias such as streptococcus, aerogenesis streptococcus, false silk streptococcus are because being subject to the inhibition of growing environment, generation is little, has therefore played the effect of prevention and treatment haze respiratory system disease.In addition, applicant also finds that in research process the salinity of its mucus returns to normal level soon, therefore be conducive to the ability that patient recovers prevention and treats pulmonary infection in the time of the high edible for patients xylitol health product of the mucus salinity of respiratory tract and lung mucosa.Although xylitol and the medicine that contains xylitol, Foods or drinks also fail to clearly demonstrate to prevention and the effective mechanism for the treatment of haze respiratory system disease, but known xylitol can suppress the growth of the harmful bacterias such as streptococcus, aerogenesis streptococcus, false silk streptococcus, simultaneously, xylitol and the medicine that contains xylitol, Foods or drinks can make the mucus salinity of respiratory tract and lung mucosa decline, and return to very soon normal level, thereby reach the effect of prevention and treatment haze respiratory system disease.
1, xylitol oral liquid
100ml xylitol oral liquid health product, Determination of Xylitol is 15g, and it is 0.3g that Fructus Momordicae extracts content, and better for sweet mouthfeel, palatability, it is water that the inventor selects to have added 1g citric acid, other surpluses, mix homogeneously, sterilizing, subpackage.
2, xylitol buccal tablet
Formula composition: xylitol 100g, arabic gum 3g, maltodextrin 2g, blue berry essence 0.16g, Fructus Momordicae extract 0.15g, vitamin C 0.05g.
Xylitol was pulverized 120 mesh sieves; mix homogeneously with maltodextrin, blue berry essence, Fructus Momordicae extract, vitamin; binding agent is made in arabic gum dilution; the raw material of above-mentioned mix homogeneously is granulated by wet granulator; 45 ℃ dry; cross 40 mesh sieve granulate, then xylitol grains is dropped into tablet machine tabletting, obtain xylitol buccal tablet.
3, xylitol dust cloud agent
Formula composition: xylitol 100g, Fructus Momordicae extract 0.1g, mix homogeneously, is crushed to grain size nanometer grade, divides and installs in Capsules, makes capsule type inhalation aerosol powder, makes every capsules containing xylitol 0.2g.When application, Xylitol compositions is placed in to nebulizer, sucks tract mucosa and pulmonary by experimenter.
This test case be in January, 2013 to 2013 year December in Yucheng City the People's Hospital through being diagnosed as the patient of haze respiratory system disease, 7-72 years old ages, totally 150 examples, clinical manifestation is the symptoms such as cough, expectoration, rhinorrhea, nasal obstruction, sneeze, dry pharynx, finds reddish tongue through health check-up, and tongue is BOHUANG slightly, pharyngeal congestion, antiadoncus, two pulmonary respiration sounds are coarse, with dry moist rale.150 routine patients are divided into 5 groups at random, and every group of 30 people, respectively organize patient's not statistically significant on sex, age and the state of an illness distribute.I group is taken xylitol sterling, and ⅡZu pulmonary gives the agent of xylitol dust cloud, and III group is taken xylitol buccal tablet, IV group is taken xylitol oral liquid, V group is taken roxithromycin dispersing tablet, and wherein I, II, III, IV group are treatment experimental group, and V group is control experiment group.Require I group, III group, IV group to take 2 times every day, xylitol products is each serving with 5 grams, xylitol buccal tablet, xylitol oral liquid are equivalent to 5 grams of xylitol dry product each serving consumption, the xylitol dust cloud agent of II group sucks 2 times every day, the each suction volume of xylitol dust cloud agent is equivalent to xylitol dry 5g, 0.15 gram/times of the roxithromycin dispersing tablet of contrast V group, every twice-daily, oral, child is cut down according to the circumstance.Laboratory observation course for the treatment of is 7 days.Concrete treatment criterion of therapeutical effect is:
Recovery from illness: treat the clinical symptoms signs such as cough in 7 days, expectoration, rhinorrhea, nasal obstruction, sneeze, dry pharynx and disappear;
Effective: to treat the clinical symptoms signs such as cough in 7 days, expectoration, rhinorrhea, nasal obstruction, sneeze, dry pharynx and alleviate more than 3/4;
Effective: to treat the clinical symptoms signs such as cough in 7 days, expectoration, rhinorrhea, nasal obstruction, sneeze, dry pharynx and alleviate 1/4-3/4;
Invalid: to treat symptom in 7 days and be all not improved or increase the weight of.
Treat that after 7 days, it the results are shown in following table.
Through 7 days, the patient's who is diagnosed as haze respiratory system disease contrast therapy is tested, treat the total effective rate of experimental group and control experiment group patient healing and observe the cough of medication Patients Before And After by calculating, expectoration, rhinorrhea, nasal obstruction, sneeze, the clinical symptoms such as dry pharynx are improved situation, as can be seen from the above table: use the treatment experimental group of product of the present invention to cure total effective rate all more than 80%, all higher than 36.7% of control experiment group, wherein using xylitol products total effective rate of the present invention is 90%, use xylitol buccal tablet of the present invention and xylitol oral liquid total effective rate also more than 83%, there is statistical significance (P<0.05) with control experiment group comparing difference, using xylitol dust cloud agent total effective rate of the present invention is 93%, the mode administration agent of xylitol dust cloud being sucked by pulmonary by nebulizer, xylitol directly arrives and is encroached on position, absorb better, effective percentage is higher.In addition, in clinical treatment observation, find no toxic and side effects.Therefore, can draw by clinical experiment result: use xylitol products of the present invention or medicine, food or oral liquid etc. containing effective ingredient xylitol, evident in efficacy aspect prevention and treatment haze respiratory system disease, in the roxithromycin dispersing tablet group that is all better than contrast aspect alleviation clinical symptoms time and total effectively cure rate, and pulmonary administration mode is better than due to oral, xylitol is edible every day as health product, for daily pulmonary, respiratory system nursing, alleviate the injury that haze occurs, can not produce any toxic and side effects.
Claims (10)
1. there is a compositions that prevents and/or treats haze respiratory system disease, it is characterized in that, contain xylitol.
2. compositions as claimed in claim 1, is characterized in that, is mainly made up of xylitol and Fructus Momordicae extract.
3. compositions as claimed in claim 2, is characterized in that, can make acceptable preparation, wherein xylitol and Fructus Momordicae extract shared percentage by weight in preparation is 0.1-99.9%.
4. compositions as claimed in claim 3, it is characterized in that, the dosage form of described compositions is selected from: tablet, sugar coated tablet, film coated tablet, enteric coated tablet, capsule, hard capsule, soft capsule, oral liquid, suck agent, granule, electuary, pill, powder, unguentum, sublimed preparation, suspensoid, powder, solution, injection, suppository, ointment, plaster, cream, spray, drop or patch.
5. compositions as claimed in claim 4, is characterized in that, during for prevention and health-care effect, selects oral, respiratory system administering mode; Do the used time when being used for the treatment of, select respiratory system administering mode.
6. compositions as claimed in claim 5, is characterized in that, the xylitol that described tablet is 90-95% by quality percentage composition, the Fructus Momordicae extract of 0.2-5% form, and other surpluses are excipient.
7. compositions as claimed in claim 6, is characterized in that, during for prevention and treatment haze respiratory system disease, the compositions that take in every day is counted 5-80g by xylitol quality.
8. compositions as claimed in claim 7, is characterized in that, the compositions that take in every day is counted 5-15g by xylitol quality.
9. compositions as claimed in claim 8, is characterized in that, the compositions that take in every day is counted 6-10g by xylitol quality.
10. compositions as claimed in claim 5, is characterized in that, in described oral liquid, the mass concentration of xylitol is 5-30%, and the mass concentration of Fructus Momordicae extract is 0.1-2%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410166161.8A CN103893240A (en) | 2014-04-24 | 2014-04-24 | Composition for preventing and/or treating respiratory system diseases caused by hazes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410166161.8A CN103893240A (en) | 2014-04-24 | 2014-04-24 | Composition for preventing and/or treating respiratory system diseases caused by hazes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103893240A true CN103893240A (en) | 2014-07-02 |
Family
ID=50985027
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410166161.8A Pending CN103893240A (en) | 2014-04-24 | 2014-04-24 | Composition for preventing and/or treating respiratory system diseases caused by hazes |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103893240A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106360782A (en) * | 2016-08-25 | 2017-02-01 | 江南大学 | Nutrient soft capsule dietary supplement having functions of preventing and repairing haze damage and preparation method thereof |
| CN110302186A (en) * | 2019-07-02 | 2019-10-08 | 桂林八加一药业股份有限公司 | A kind of Momordia grosvenori aglycone aerosol and preparation method thereof |
-
2014
- 2014-04-24 CN CN201410166161.8A patent/CN103893240A/en active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106360782A (en) * | 2016-08-25 | 2017-02-01 | 江南大学 | Nutrient soft capsule dietary supplement having functions of preventing and repairing haze damage and preparation method thereof |
| CN106360782B (en) * | 2016-08-25 | 2018-07-10 | 江南大学 | A kind of nutrition cellulose soft capsules dietary supplements for having the function of to prevent and repairing haze damage and preparation method thereof |
| CN110302186A (en) * | 2019-07-02 | 2019-10-08 | 桂林八加一药业股份有限公司 | A kind of Momordia grosvenori aglycone aerosol and preparation method thereof |
| CN110302186B (en) * | 2019-07-02 | 2021-11-16 | 桂林八加一药业股份有限公司 | Mogroside aerosol and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6345243B2 (en) | Enbu fermented food or beverage composition | |
| WO2013013496A1 (en) | Drink composition for clearing inner heat and preparation method thereof | |
| CN107617061A (en) | A kind of composition with clearing lung-heat moistening lung function and preparation method thereof | |
| CN101322761B (en) | Medicament for treating tracheitis and bronchitic and preparation thereof | |
| CN105168807B (en) | The Chinese medicine composition and preparation method thereof for treating pig blue-ear disease | |
| CN106511740B (en) | A kind of product and preparation method thereof comprising ginseng | |
| CN108523121A (en) | A kind of functional food and preparation method thereof of anti-haze clearing lung-heat | |
| CN103893240A (en) | Composition for preventing and/or treating respiratory system diseases caused by hazes | |
| CN105535406A (en) | Traditional Chinese medicine composition for preventing and treating livestock respiratory disease | |
| CN103705890A (en) | Pharmaceutical composition with function of removing heat from lung to relieve cough | |
| CN106421486A (en) | Veterinary traditional Chinese medicine composition with heat clearing and toxicity removing effects and preparation method thereof | |
| CN105726920A (en) | Anti-PM2.5 chewable tablets and preparing method thereof | |
| CN102614269B (en) | Method for preparing traditional Tibetan medicine for treating pharyngitis | |
| CN102641335A (en) | Traditional Chinese medicine composition for treating upper respiratory tract viral infection and preparation method thereof | |
| KR20200082648A (en) | A composition for improving, preventing and treating of asthmatic containing oriental medicine herbs oil extract as an active ingredient | |
| CN106511491B (en) | A kind of composition and preparation method thereof, application, preparation | |
| CN101209293A (en) | Chinese medicinal granule with heat-clearing, detoxication, wind-expelling and cold-expelling efficacy | |
| CN103893158A (en) | Application of xylitol in diseases of respiratory system caused by haze | |
| CN112168947A (en) | Traditional Chinese medicine composition for treating pneumonia and preparation method thereof | |
| CN107158286B (en) | Traditional Chinese medicine composition for treating respiratory tract injury induced symptoms caused by haze and preparation method thereof | |
| CN110302276A (en) | It is a kind of for preventing and treating the Chinese medicine composition and preparation method thereof of chicken pneumonia | |
| CN113425767B (en) | Traditional Chinese medicine composition for treating pneumonia | |
| CN109662184A (en) | A kind of candy and preparation method thereof that suitable smoking personage eats | |
| CN113101331B (en) | Thyme herb tea and preparation method and application thereof | |
| CN108125237A (en) | A kind of anti-inflammatory health products of kobadrin and its preparation process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20151023 Address after: 266031, 1001/1002 building, 177 Shandong Road, Sifang Road, Sifang, Shandong, Qingdao Applicant after: Shandong Futaste Technology Group Co., Ltd. Address before: 251200 Yucheng, Shandong, South Ring Road, No. 666, No. Applicant before: Shandong Futian Medicine Industry Co., Ltd. |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20160705 Address after: 266000 Shandong province Qingdao City, Shandong Road No. 177 1002 Applicant after: Shandong Mifutang Food Co., Ltd. Address before: 266031, 1001/1002 building, 177 Shandong Road, Sifang Road, Sifang, Shandong, Qingdao Applicant before: Shandong Futaste Technology Group Co., Ltd. |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20161031 Address after: Three road 266000 in Shandong province Qingdao city Yanan No. 234 Building No. 1 room 1808 Applicant after: Qingdao Health Technology Co., Ltd. Address before: 266000 Shandong province Qingdao City, Shandong Road No. 177 1002 Applicant before: Shandong Mifutang Food Co., Ltd. |
|
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140702 |
|
| RJ01 | Rejection of invention patent application after publication |